Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Assessment 2024 | Clinical Trials, Latest Approvals, Key Players | Sanofi, Johnson & Johnson, Immunovant, UCB S.A., GeNeuro

Major pharmaceutical and biotechnology giants such as Argenx, Sanofi, Takeda, and others are introducing novel therapeutic approaches that could completely change the treatment landscape of CIDP. If launched, these emerging potential candidates could pose a significant challenge to current CIDP treatments.
DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy- Pipeline Insight, 2024 [https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Chronic Inflammatory Demyelinating Polyneuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The CIDP treatment landscape is continually evolving, with several companies aggressively working toward the development of new treatments that could potentially cure the disease and transform its treatment landscape. Companies are focusing on the development of FcRN targeting therapies for CIDP, which is expected to have a positive impact on the market size of the disease in the coming years.

Major pharmaceutical and biotechnology giants such as Argenx, Sanofi, Takeda, and others are introducing novel therapeutic approaches that could completely change the treatment landscape of CIDP. If launched, these emerging potential candidates could pose a significant challenge to current CIDP treatments.

"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Insight, 2024" report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Chronic Inflammatory Demyelinating Polyneuropathy Market.

The Chronic Inflammatory Demyelinating Polyneuropathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Chronic Inflammatory Demyelinating Polyneuropathy Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP), also known as chronic inflammatory demyelinating polyradiculoneuropathy, is an autoimmune-mediated inflammatory disease that affects the peripheral nerves and nerve roots. This disorder is characterized by damage to the myelin sheath-the fatty covering that protects nerve fibers-and by immune infiltrates. CIDP leads to progressive motor and sensory deficits, manifesting as proximal and distal muscle weakness, numbness, paraesthesia, sensory ataxia, and often severe disability, which are hallmarks of severe demyelination and secondary axonal loss in peripheral nerves. The disease has a slow onset and continues to progress over more than two months, typically evolving as a relapsing, progressive, or monophasic disorder.

The pathogenesis of CIDP is not fully understood. Immuno-mediated inflammatory mechanisms have been proposed, involving macrophages and proteases, which secrete reactive oxygen species, cytokines, and T lymphocytes. The role of autoantibodies has also been suggested. CIDP can follow various infections, including Campylobacter jejuni, which is more frequently associated with Guillain-Barre syndrome (GBS), an inflammatory neuropathy sharing major features with CIDP. Studies have shown molecular similarity between a component of Campylobacter jejuni and GM1, one of the targets of the autoantibodies found in patients, suggesting a role of molecular mimicry by foreign epitopes in the pathogenesis of the disease. The deposition of autoantibodies at peripheral nerve components could trigger the phagocytosis of myelin by macrophages via the recognition of immunoglobulin (Ig) fragment crystallizable receptor (FcR), leading to the activation of the complement cascade and resulting axonal damage. Antibodies to LM1, a ganglioside localized in peripheral nerve myelin, and LM1-containing ganglioside complexes, or pathogenic IgG4 autoantibodies to nodal or paranodal junction proteins, such as neurofascin 155 and 186, gliomedin, and contactin 1, have been described in CIDP. However, their low prevalence in a minority of patients with CIDP precludes them from being considered as possible biomarkers and does not permit the elaboration of pathophysiological considerations based on the antigens they target. The prognosis of CIDP is variable and depends on factors such as age, the clinical course, responsiveness to treatment, and electrophysiological findings.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Analysis [https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

The report provides insights into:

*
The report provides detailed insights into the emerging therapies for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy and the aggregate therapies developed by major pharma companies.

*
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

*
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Chronic Inflammatory Demyelinating Polyneuropathy market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like -

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Route of Administration

Chronic Inflammatory Demyelinating Polyneuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Molecule Types

Products have been categorized under various Molecule types, such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Mechanism of Action of the Emerging Pipeline Therapies

*
Complement C1s inhibitors

*
Amyloid beta-protein inhibitors

*
Neonatal Fc receptor antagonists

*
Antibody-dependent cell cytotoxicity

*
Toll-like receptor 4 antagonists

*
Immunomodulators

*
Regulatory T-lymphocyte replacements

Learn How the Ongoing Clinical & Commercial Activities will Affect the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutic Segment @ https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Landscape

According to DelveInsight, the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) therapeutics market is expected to evolve significantly in the coming years due to the growing prevalent population and increased awareness among CIDP patients in the 7MM (seven major markets). Additionally, the development of advanced technologies will further drive robust growth in the market.

Current treatments for CIDP have several limitations, including high costs, the challenge of finding the right therapeutic window to balance effectiveness with adverse events (AEs) when using corticosteroids and immunosuppressive agents, the heterogeneous nature of the disease, and the resistance or non-response of some patients to common medications over time. These factors highlight a substantial unmet need for drug development in CIDP.

Currently, Takeda is leading the therapeutics market with its Chronic Inflammatory Demyelinating Polyneuropathy drug candidates in the most advanced stages of clinical development.

Leading Companies in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Therapeutics Market Include:

Argenx, Bioasis Technologies, Inc., Biogen Idec, Cellenkos, CSL Behring, GeNeuro SA, Grifols, HarbourBioMed, Immunovant, Johnson & Johnson Services, Kedrion Biopharma, LFB, MedDay Pharmaceuticals, Momenta Pharmaceuticals, Nanjing IASO Biotherapeutics, Nihon Pharmaceutical, OctaPharma, Pfizer, Sanodi, Shire/ Takeda, Teijin Pharma, UCB Biopharma, and many others.

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Emerging and Pipeline Therapies Covered in the Report Include:

*
Batoclimab: Harbour BioMed

*
CK0803:Cellenkos

*
Efgartigimod: Argenx

*
HYQVIA: Takeda

*
PF-06755347: Pfizer

*
Rituximab: Biogen Idec

*
Rozanolixizumab: UCB S.A.

*
SAR445088: Sanodi

*
Temelimab: GeNeuro SA

*
Hizentra: CSL Behring

*
Gamunex-C: Grifols/Kedrion Biopharma

*
Kenketsu Glovenin-I: Nihon Pharmaceutical

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. Chronic Inflammatory Demyelinating Polyneuropathy Current Treatment Patterns

4. Chronic Inflammatory Demyelinating Polyneuropathy - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Chronic Inflammatory Demyelinating Polyneuropathy Late Stage Products (Phase-III)

7. Chronic Inflammatory Demyelinating Polyneuropathy Mid-Stage Products (Phase-II)

8. Chronic Inflammatory Demyelinating Polyneuropathy Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Chronic Inflammatory Demyelinating Polyneuropathy Discontinued Products

13. Chronic Inflammatory Demyelinating Polyneuropathy Product Profiles

14. Key Companies in the Chronic Inflammatory Demyelinating Polyneuropathy Market

15. Key Products in the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Segment

16. Dormant and Discontinued Products

17. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs

18. Chronic Inflammatory Demyelinating Polyneuropathy Future Perspectives

19. Chronic Inflammatory Demyelinating Polyneuropathy Analyst Review

20. Appendix

21. Report Methodology

Download a sample report: https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-inflammatory-demyelinating-polyneuropathy-pipeline-assessment-2024-clinical-trials-latest-approvals-key-players-sanofi-johnson-johnson-immunovant-ucb-sa-geneuro]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.